Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Period circadian regulator 1 (PER1) is a core transcriptional regulator of the mammalian circadian clock, orchestrating cell autonomous 24-hour oscillations in gene expression, especially in the suprachiasmatic nucleus and peripheral tissues. PER1 protein functions in a feedback loop: activated by the CLOCK/BMAL1 complex, it heterodimerizes with CRY proteins and translocates to the nucleus, where it inhibits its own transcription and other clock gene expression, ensuring rhythmic cycles. Post-translational modifications, like CK1ε/δ phosphorylation and ubiquitin-mediated proteasomal degradation, fine-tune its abundance and timing. PER1 is implicated as a tumor suppressor, with loss or downregulation associated with proliferation, impaired apoptosis, altered DNA repair, and therapy resistance in various cancers. Additional roles include mediating metabolic responses to toxins, modulating glucocorticoid signaling, and influencing neurobehavioral phenotypes through clock gene regulation.
Mechanism of action for drugs targeting PER1 would involve chronotherapeutics (modulation of PER1 expression or function to restore normal circadian gene expression cycles, enhance apoptosis, and suppress tumor growth). This can include epigenetic modulation (altering promoter methylation to restore PER1 expression, especially in cancer), protein-protein interaction disruption (targeting feedback inhibition mechanisms, e.g., PER/CRY interaction with CLOCK-BMAL1), or modulation of metabolic regulators (e.g., interaction with HNF-1α to regulate CYP2E1-mediated toxin metabolism).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Period circadian regulator 1 (PER1).